申请人:MOCHIDA PHARMACEUTICAL CO., LTD.
公开号:US20140378447A1
公开(公告)日:2014-12-25
It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
已经有人希望开发一种药物组合物,用于预防和/或治疗与PDE10相关的各种疾病(例如精神障碍和神经退行性疾病)。本发明提供:具有PDE10抑制作用的化合物,特别是具有以下式(I)所代表的4-杂环芳基吡唑-5-羧酰胺结构的化合物,或其药学上可接受的盐,或其溶剂化物;包含作为活性成分的化合物,或其药学上可接受的盐,或其溶剂化物的药物组合物;以及化合物的医学用途,或其药学上可接受的盐,或其溶剂化物。